Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential gene expression in murine lung cancer in vitro vs. in vivo

ABSTRACT: The tumor microenvironment (TME) is incredibly important to the growth of tumors. To better understand the effect that the TME has on cancer cells, we assessed genes that were differentially expressed in murine lung tumors versus cells that were cultured in an incubator. We employed our orthotopic mouse model where murine lung cancer cells were implanted into the left lung of immunocompetent, syngeneic GFP-expressing mice of the C57BL/6 strain. After 3-4 weeks, tumors were harvested and a single cell suspension was prepared from the tumors. Using fluorescent-activated cell sorting, live (DAPI-negative), GFP-negative cells were isolated from the single cell suspensions. These GFP-negative cells constitute a pure population of tumor cells, excluding cells from the TME. RNA was isolated from these tumor cells, and submitted to RNA-seq. These are our “in vivo” samples. Concurrently, the cells from the same batch of cells that were initially injected into mice were cultured in vitro, and RNA was isolated from them and submitted to RNA-seq. These samples are our “in vitro” samples. Our study specifically utilizes 2 newly developed EML4-ALK fusion-driven murine lung cancer cell lines (EA1 and EA2 cells).

ORGANISM(S): Mus musculus

PROVIDER: GSE204918 | GEO | 2022/05/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional signatures associated with in vivo growth of lung cancer cells

Project description:Interactions between cancer cells and the host cells in the tumor microenvironment (TME) are critical for tumor growth and metastasis. While the host cells have been widely studied within the TME, cancer cell have been mostly studied in vitro. We hypothesized that the growth of cancer cells in vivo results in specific changes in cancer cells’ transcriptome that reflect specific interactions between cancer cell and the TME. To begin to define the changes in cancer cells growing in vivo, we performed RNA-seq transcriptome analysis of cancer cells isolated from murine tumors and compared them to transcriptomes of cells growing in vitro. In this study we used two murine lung cancer cell lines, both derived from a spontaneous lung adenocarcinoma in C57BL/6 mouse: (1) Lewis Lung carcinoma (LLC) and (2) CMT167(CMT). We first harvested RNA from these 2 cell lines cultured in vitro. To assess the transcriptome of cells growing in vivo, we employed an orthotopic immunocompetent model of lung adenocarcinoma in which murine lung cancer cells are directly implanted into the left lobe of syngeneic mice. LLC or CMT cells were injected into the lung of GFP-expressing mice of C57BL/6 strain. Resulting tumors were harvested, processed into single cell suspension, and cancer cells were isolated from host cells by flow cytometry, sorting for GFP-negative cells. RNA was extracted from freshly isolated cells. Furthermore, to assess if the changes associated with in vivo growth are permanent, we re-plated the cells isolated from mice, cultured them further in vitro, and extracted their RNA. Our RNA-seq analysis has shown that both cell lines undergo robust specific changes in transcriptional profile when growing in vivo as compared to cells cultured in vitro. Majority of these signatures were reversed in cells that were replated and further cultured in vitro after isolation from mice.

2019-05-23 | GSE100412 | GEO

ECM-enriched mouse lung - TMT-based quantitative mass spectrometry analysis was performed on ECM-enriched preparation from normal murine lung, bleomycin-induced fibrotic lung, primary tumors and lymph node metastasis isolated from the KrasG12D/+p53-/- mouse model of lung adenocarcinoma. Three independent samples were processed and analyzed for each condition. This study identified ECM signatures of normal and diseased lung tissue.

Project description:TMT-based quantitative mass spectrometry analysis was performed on ECM-enriched preparation from normal murine lung, bleomycin-induced fibrotic lung, primary tumors and lymph node metastasis isolated from the KrasG12D/+p53-/- mouse model of lung adenocarcinoma. Three independent samples were processed and analyzed for each condition. This study identified ECM signatures of normal and diseased lung tissue.

2017-06-21 | PXD003517 | Pride

Transcriptome profiling of SUM159 and derivatives with different metastasis capability

Project description:Triple negative breast cancer cell line SUM159 labeled with triple reporter (TR, TK-GFP-fLUC) injected into Nude mice via mammary fat pad and tail vein injection. Tumor progression is monitored by in vivo bioluminescent imaging. Tumors from mammary and lung were isolated and cultured. These derivatives cells are further tested for their capability to develop mammary primary tumor and metastasis in lung and bone in mice. The total RNA samples are extracted from the panel of SUM159 and derivatives and the transcriptome profiles are determined by microarray. The correlation of transcriptome of the cells to metastasis capability indicated candidate genes and regulatory pathways of metastasis of TNBC.

2021-01-13 | GSE151198 | GEO

Nkx2-1 Represses a Latent Gastric Differentiation Program in Lung Adenocarcinoma

Project description:Tissue-specific differentiation programs become dysregulated during cancer evolution. The transcription factor Nkx2-1 is a master regulator of pulmonary differentiation that is downregulated in poorly differentiated lung adenocarcinoma. Here we use conditional murine genetics to study the fate of lung epithelial cells upon loss of their master cell fate regulator. Nkx2-1 deletion in normal and neoplastic lung causes not only loss of pulmonary identity but also gastric transdifferentiation. Nkx2-1 maintains pulmonary identity by sequestering the Foxa1 transcription factor at lung-specific loci and by inhibiting Foxa1 binding to gastrointestinal targets. Murine Nkx2-1-negative lung tumors mimic the mucinous subtype of human lung adenocarcinoma, which also exhibits gastric transdifferentiation. Nkx2-1-negative lung adenocarcinomas are dependent on the gastrointestinal gene Hnf4a for efficient initiation. Thus, loss of Nkx2-1 causes transdifferentiation rather than stable dedifferentiation in vivo, suggesting that inactivation of both active and latent differentiation programs are required for tumors to reach a primitive, dedifferentiated state. ChIP-seq data from murine lung adenocarcinomas on (i) transcription factors Nkx2-1 and Foxa in Nkx2-1-deleted tumors and Nkx2-1-positive control tumors, and (ii) four histone marks in Nkx2-1-deleted tumors and Nkx2-1-positive control tumors. (All samples in duplicate and with input controls, i.e. (2 x [(3+3) + (2+8)]) - 1 = 31 samples total - 1 input control used for transcription factor and histone mark, GSM1059357)

2013-04-09 | E-GEOD-43252 | biostudies-arrayexpress

Methylation analysis of 12 corresponding pairs of TECs and NECs isolated from human CRC patients with different prognostic TMEs

Project description:Methylation analysis of 12 corresponding pairs of tumor endothelial cells (TECs) and normal endothelial cells (NECs) isolated from human colorectal carcinoma (CRC) patients with different prognostic tumor microenvironments (TMEs: Th1-TME vs Control-TME): High and low GBP-1 expression in the tumors detected by IHC was used to categorize the patient-derived cells into Th1-TME and Control-TME (compare Naschberger et al, J Clin Invest 2016 and Naschberger et al, Int J Cancer 2008). Isolation of the samples was done according to Naschberger et al, JoVE 2018. The analysis is paralleled by omics-analysis of the same cell cultures at the transcriptome (E-MTAB-10465) and genome level (E-MEXP-3993).

2023-05-01 | E-MTAB-10467 | biostudies-arrayexpress

Expression data from 4T1 subclones derived from mammary fat pad tumors (MFP), axillary lymph node tumors (AxLN), and axillary lymph node-derived lung metastases (AxLN-LuM)

Project description:Expression data from 4T1 subclones derived from mammary fat pad tumors (MFP), axillary lymph node tumors (AxLN), and axillary lymph node-derived lung metastases (AxLN-LuM). In parallel, expression data, in the same subclones, of tail vein-derived (TV) lung metastases. The mechanism of how lymph node metastases seed distant metastases is unknown. We used the 4T1 breast cancer cell line, which is an immune competent model of triple negative breast cancer and spontaneously metastasizes in balb/c mice. 4T1-GFP/fLuc cells were injected into MFP to form tumors and 4T1-mCherry/rLuc cells were injected into axillary lymph nodes to form tumors and then allowed to metastasize to lung. TV cells were allowed to metastasize in the lung. Cells were harvested at different time intervals after the injection. Tumors were extracted, dissociated, and then expanded in vitro to obtain MFP, AxLN, AxLN-LuM and TV-LuM subclones isolated after different time lags with respect to the injection.

2019-08-20 | GSE136031 | GEO

Gene Changes Following in vitro Alectinib Treatment in EML4-ALK Murine NSCLC Cells

Project description:First line treatment for EML4-ALK fusion-positive lung cancer patient is the use of an ALK tyrosine kinase inhibitor (TKI), such as alectinib. While most patients initially respond to this therapy, many patients often develop relapse, and efficacious therapies for patients with relapse disease are limited. To study EML4-ALK fusion-positive lung cancer, novel murine lung cancer cell lines were generated from C57BL/6 mice using an intratracheally injected Adeno-virus that contains Cas9 and guide RNAs for the EML4-ALK translocation, which leads to the development of lung tumors. Cell lines were derived from these tumors. In an effort to better understand how cells respond to alectinib, we treated EML4-ALK-positive murine cell lines (EA1, EA2, and EA3 cells) in vitro for 1-7 days with either 100nM alectinib or DMSO-control. At each time point, RNA was isolated from each condition. RNA was submitted to RNA-seq. Differential analysis on the RNA-seq data was performed to determine and track gene changes over time between control and treated cells. These data will allow us to better develop novel therapeutics to use in conjunction with alectinib when treating EML4-ALK fusion-positive patients.

2022-11-05 | GSE217115 | GEO

Proteomic Signatures of Myeloid Derived Suppressor Cells from Liver and Lung Metastases Reveal Functional Divergence and Potential Therapeutic Targets

Project description:Myeloid Derived Suppressor Cells (MDSCs) promote immunosuppressive activities in the tumor microenvironment (TME), resulting in increased tumor burden and diminishing the anti-tumor response of immunotherapies. While primary and metastatic tumors are typically the focal points of therapeutic development, the immune cells of the TME are uniquely programmed by the tissue of the metastatic site. In particular, MDSCs are programmed uniquely within different organs in the context of tumor progression. Given that MDSC plasticity is shaped by the surrounding environment, the proteome of MDSCs from different metastatic sites are hypothesized to be unique. A bottom-up proteomics approach using Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) was used to quantify the proteome of CD11b+ cells derived from murine liver metastases (LM) and lung metastases (LuM). A comparative proteomics workflow was employed to compare MDSC proteins from LuM (LuM-MDSC) and LM (LM-MDSC) while also elucidating common signaling pathways, protein function, and possible drug-protein interactions.

2021-11-03 | PXD023337 | Pride

Gene expression profiling of Sox2+ Patched1+/- medulloblastoma cells

Project description:Only a minority of medulloblastoma cells can self-renew and sustain tumor growth. In the Patched1+/- mouse model, these cells are quiescent and express the stem cell marker Sox2. We sought to define the gene expression profiling of these cells to gain insight into the molecular pathways that govern this population. Sox2-expressing and Sox2-negative cells were isolated from primary Sox2-eGFP;Patched1+/- tumors as GFP+ or GFP- tumors, respectively.

2016-07-08 | GSE48766 | GEO

Cancer-cell transcriptional signatures associated with Socs1 knockdown in an immunocompetent and orthotopic mouse model of non-small lung cancer

Project description:How cancer cells respond to signals coming from the tumor microenvironment cannot be fully elucidated in vitro. Additionally, RNA-Sequencing data from bulk human tumors does not assess the contribution of cancer cells alone, but from a complex mixture of both host and cancer cells. Using an immunocompetent and orthotopic mouse model of human Non-small Cell Lung Cancer, we sought to determine cancer cell specific transcriptomes from bulk tumors and compared these to cancer cells grown in vitro. We hypothesized that knockdown of Socs1, or suppressor of cytokine signaling 1 in Lewis Lung Carcinoma (LLC) cells would not only impact their response to single-agent immunotherapy, but also lead to complex changes in the tumor microenvironment. First, we harvested RNA from either LLC-NT (LLC cells transduced with a non-targeting control vector) or LLC-sh21 (LLC cells transduced with a Socs1 knockdown vector) cell lines grown in vitro. To determine the transcriptome of these cells grown in vivo, we injected LLC-NT or LLC-sh21 cells into the left lung of transgenic GFP-expressing C57BL/6J mice. After three weeks, tumor-bearing lung lobes were isolated from mice and were made into single cell suspensions. The GFP-negative cancer cell population was sorted from GFP-positive host cells by fluorescence activated cell sorting. RNA was extracted from freshly isolated cancer cells grown in vitro or from cancer cells isolated from tumors. Our RNA-seq analysis shows that LLC-sh21 cells respond to IFNg coming from the microenvironment relative to LLC-NT cells which have a blunted response due to high basal expression of SOCS1. These data suggest that specific genes in the IFNg response pathway are important for response to immunotherapy.

2019-05-23 | GSE131271 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data